{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-inhaled/background-information/action-of-inhaled-corticosteroids/","result":{"pageContext":{"chapter":{"id":"05a81ed7-5f38-5cdb-9632-25d4c2e2bdcc","slug":"action-of-inhaled-corticosteroids","fullItemName":"Action of inhaled corticosteroids","depth":2,"htmlHeader":"<!-- begin field 73d4761b-4367-4ebc-abc1-bf80716f8cac --><h2>How do inhaled corticosteroids work?</h2><!-- end field 73d4761b-4367-4ebc-abc1-bf80716f8cac -->","summary":"","htmlStringContent":"<!-- begin item b3151fc2-07e6-480f-ab59-272744910961 --><!-- begin field 9de6023d-d11e-4b57-a4f0-c9a797a3acc6 --><ul><li><strong>Corticosteroids have mineralocorticoid and glucocorticoid properties</strong> — the effects of different corticosteroids vary qualitatively as well as quantitatively.</li><li><strong>Mineralocorticoid effects include: </strong><ul><li>Increased sodium and water retention.</li><li>Increased potassium and hydrogen ion loss. </li></ul></li><li><strong>Glucocorticoid effects include: </strong><ul><li>Metabolic actions — decreased uptake and utilization of glucose and increased gluconeogenesis; decreased protein synthesis and increased protein breakdown; a permissive effect on lipolytic hormones and a redistribution of fat (observed in Cushing's syndrome); and decreased calcium stores.</li><li>Regulatory actions:<ul><li>Anti-inflammatory and immunosuppressive — decreased production of inflammatory mediators (such as prostaglandins and cytokines); decreased production of histamine and other mediators from basophils and mast cells; decreased production of immunoglobulin G (IgG); decreased egress of neutrophils from blood vessels and reduced activation; and decreased activation of T-lymphocytes.</li><li>Cardiovascular — reduced vasodilation, decreased fluid exudation. </li><li>Musculoskeletal — decreased osteoblast and increased osteoclast activity.</li></ul></li></ul></li><li><strong>Inhaled corticosteroids have potent anti-inflammatory activity</strong> — they inhibit or prevent inflammatory components of both the immediate and late phases of asthma. Inhaled corticosteroids:<ul><li>Decrease formation of cytokines (an inflammatory mediator). </li><li>Decrease microvascular permeability.</li><li>Inhibit influx of eosinophils into the lung (reducing overall inflammation). </li><li>Reduce bronchial hyper-responsiveness. </li></ul></li><li>Inhaled corticosteroids are delivered directly into the lungs (via a variety of devices), which reduces systemic absorption and the risk of adverse effects compared with oral corticosteroids (see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>).<ul><li>However, in people on high-dose, long-term therapy, some systemic absorption will occur potentially leading to adverse effects.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-inhaled/references/\">Atack, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-inhaled/references/\">Brown, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-inhaled/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-inhaled/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-inhaled/references/\">Brayfield, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-inhaled/references/\">Ritter, 2020</a>]</p><!-- end field 9de6023d-d11e-4b57-a4f0-c9a797a3acc6 --><!-- end item b3151fc2-07e6-480f-ab59-272744910961 -->","topic":{"id":"754932e3-62ea-5d15-b61d-d5a5d6f4fe71","topicId":"702fbe32-706c-43c3-bc60-c5cc8f25f0a7","topicName":"Corticosteroids - inhaled","slug":"corticosteroids-inhaled","lastRevised":"Last revised in May 2020","chapters":[{"id":"e16eda3c-cfc9-5314-bbcf-81f1103a5e06","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"efb2ce33-0722-5c31-9322-cba88887d787","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"39f35fad-0659-5902-87b2-552b35242d2d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2f4cdb72-e152-55d0-ae30-3f5af0898296","slug":"changes","fullItemName":"Changes"},{"id":"efff15e7-d3fb-5f90-b3f8-6e71440ba7a9","slug":"update","fullItemName":"Update"}]},{"id":"1cb3cdc7-d58b-55c4-a4dc-45e54579d133","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"416f2419-bb3a-58d9-aea2-5f7507d47ae6","slug":"goals","fullItemName":"Goals"},{"id":"f0acbcc7-6859-5e5a-97f1-55768a7a7112","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e5608261-290b-5500-aec0-ba1898b40aa8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"627a8419-15f6-51a5-bd61-09cd8079faaa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8650965c-ede6-5616-a913-25e614b34788","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a1969d6e-782d-5f6b-aa7a-865b57819d63","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d64ef1a8-021d-5652-a94f-b6a774c0859a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"09abff45-ce37-5d8b-aa7a-22ccb00d395b","slug":"definition","fullItemName":"Definition"},{"id":"05a81ed7-5f38-5cdb-9632-25d4c2e2bdcc","slug":"action-of-inhaled-corticosteroids","fullItemName":"Action of inhaled corticosteroids"},{"id":"64e8ade1-73c2-542d-b449-ad660d98768b","slug":"types-of-inhaled-corticosteroids","fullItemName":"Types of inhaled corticosteroids"}]},{"id":"91b69720-7ebf-581e-982f-dbdd23431ed6","fullItemName":"Management","slug":"management","subChapters":[{"id":"a547f7e2-e032-5c44-8261-cea196fc4d68","slug":"corticosteroids-inhaled","fullItemName":"Scenario: Corticosteroids - inhaled"}]},{"id":"bd9a7839-1db9-5989-b6e2-1dca5e05011d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"911e76ba-1f8e-5933-9443-46079dc58b6e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c1740827-55f4-59ff-be70-58d37950d253","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"89f98a44-5528-5143-a4a4-7191fb4e63a5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1f364ad-9716-533d-be8e-e76d8756114d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f271d3a7-f87a-5588-ba5e-8a5f5a6f9cb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ac4dbca5-4c83-52b2-b0ac-a8b7bd478cf0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ccd99bc8-bb83-57ec-be29-e083eabb4915","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d64ef1a8-021d-5652-a94f-b6a774c0859a","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}